Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$67.91 USD

67.91
1,223,958

+0.75 (1.12%)

Updated Aug 4, 2025 03:59 PM ET

After-Market: $67.90 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Hologic (HOLX) Beats on Q1 Earnings, Lowers '17 Guidance

by Zacks Equity Research

Hologic Inc. (HOLX) reported first-quarter fiscal 2017 adjusted earnings per share (EPS) of 52 cents, up 13% year over year.

    Zacks Equity Research

    Medical Instrument Stocks' Earnings on Feb 1: EW, HOLX, BABY

    by Zacks Equity Research

    Already more than one-third of the S&P 500 members (170 companies making up for 19.2% of the total market cap) have reported their Oct--Dec 2016 quarter's earnings results.

      John Blank headshot

      4 Good Reasons to Focus on the USA: Global Week Ahead

      by John Blank

      In the Global Week Ahead, the bulk of any trader???s time should focus on the good ol' USA. Why do we think that? There are four old-fashioned reasons.

        Zacks Equity Research

        Abiomed (ABMD) Beats Earnings & Revenue Estimates in Q3

        by Zacks Equity Research

        Abiomed Inc. (ABMD) reported third-quarter fiscal 2017 earnings of 34 cents per share, which surpassed the Zacks Consensus Estimate by 5 cents and surged 47.8% from the year-ago quarter.

          Zacks Equity Research

          C.R. Bard (BCR) Q4 Earnings & Sales Better Than Expected

          by Zacks Equity Research

          C.R. Bard Inc. (BCR) reported adjusted earnings of $2.77 in the fourth quarter of 2016, exceeding the Zacks Consensus Estimate by 4 cents and improving from the year-ago quarterly number of $2.43.

            Zacks Equity Research

            Quality Systems (QSII) Beats on Earnings & Revenues in Q3

            by Zacks Equity Research

            Irvine, CA-based Quality Systems Inc. (QSII) reported third-quarter fiscal 2017 adjusted earnings of 21 cents per share, exceeding the Zacks Consensus Estimate of 18 cents.

              Zacks Equity Research

              Varian Medical (VAR) Misses on Q1 Earnings and Revenues

              by Zacks Equity Research

              Varian Medical Systems, Inc. (VAR) reported adjusted earnings of 75 cents per share in the first quarter of fiscal 2017.

                Zacks Equity Research

                McKesson (MCK) Beats on Earnings in Q3, Inks Buyout Deal

                by Zacks Equity Research

                McKesson Corporation (MCK) reported third-quarter fiscal 2017 earnings of $3.03 per share, beating the Zacks Consensus Estimate of $2.95 but declining from the year-ago figure of $3.18.

                  Zacks Equity Research

                  Stryker (SYK) Beats Q4 Earnings, Provides FY17 Guidance

                  by Zacks Equity Research

                  Maintaining its streak of positive earnings surprises, Stryker Corp (SYK) reported adjusted earnings of $1.78 per share in the fourth quarter of 2016, which comfortably beat the Zacks Consensus Estimate by 2 cents.

                    Zacks Equity Research

                    Intuitive Surgical (ISRG) Beats on Q4 Earnings & Revenues

                    by Zacks Equity Research

                    Intuitive Surgical Inc. (ISRG) posted adjusted earnings of $5.30 per share in the fourth quarter of 2016, beating the Zacks Consensus Estimate by four cents.

                      Zacks Equity Research

                      Is a Surprise in Store for Hologic (HOLX) in Q1 Earnings?

                      by Zacks Equity Research

                      Hologic Inc. (HOLX) is slated to report first-quarter fiscal 2017 financial results on Feb 1, after the closing bell.

                        Zacks Equity Research

                        The Zacks Analyst Blog Highlights: Intuitive Surgical, Stryker and Hologic

                        by Zacks Equity Research

                        The Zacks Analyst Blog Highlights: Intuitive Surgical, Stryker and Hologic

                          Zacks Equity Research

                          3 Medical Device Stocks Likely to Beat Earnings Estimates

                          by Zacks Equity Research

                          The likely revocation of the 2.3% medical device excise tax is going to be a big bonus for both the behemoths and small players.

                            Zacks Equity Research

                            Hologic (HOLX) Receives PMA for Aptima HIV-1 Quant Assay

                            by Zacks Equity Research

                            Hologic, Inc. (HOLX) recently announced the receipt of the FDAs Premarket Approval (PMA) for its Aptima HIV-1 Quant assay.

                              Zacks Equity Research

                              Hologic (HOLX) to Divest Blood Screening Business to Grifols

                              by Zacks Equity Research

                              Hologic, Inc. (HOLX) recently inked a deal to divest its stake in the blood screening business.

                                Zacks Equity Research

                                Hologic Hits 52-Week High on Q4 Earnings & Solid Prospects

                                by Zacks Equity Research

                                Share price of Bedford, MA-based Hologic Inc. (HOLX) reached a new 52-week high of $41.01 on Dec 14, finally closing a tad lower at $40.79.

                                  Zacks Equity Research

                                  Whole Foods (WFM) Will No Longer be Part of Nasdaq-100

                                  by Zacks Equity Research

                                  As a result of the annual re-ranking of the NASDAQ-100 index, Whole Foods (WFM) will cease to be a part of the same.

                                    Zacks Equity Research

                                    Bed Bath and Beyond (BBBY) Loses its Place in Nasdaq-100

                                    by Zacks Equity Research

                                    The NASDAQ-100 Index as part of its annual re-ranking process has decided to remove Bed, Bath & Beyond Inc. (BBBY).

                                      Zacks Equity Research

                                      4 Medical Instrument Stocks to Bet on This Earnings Season

                                      by Zacks Equity Research

                                      The medical instrument sector holds a lot of promise at this moment.

                                        Zacks Equity Research

                                        Top 3 MedTech Stocks Poised to Gain this Earnings Season

                                        by Zacks Equity Research

                                        A bipartisan group of ten senators signed on a bill to repeal the 2.3% federal excise tax on medical device makers.